

CITATION REPORT

List of articles citing

Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomech

DOI: 10.1016/j.joms.2010.07.017

Journal of Oral and Maxillofacial Surgery, 2010, 68, 2837-45.

Source: <https://exaly.com/paper-pdf/48002218/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
116	Current world literature. 2011 , 19, 322-8		
115	Geranylgeraniol - a new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw. 2011 , 47, 195-201		42
114	Bisphosphonate related osteonecrosis of the jaw--manifestation in a microvascular iliac bone flap. 2011 , 47, 425-9		28
113	Increased human defensin levels hint at an inflammatory etiology of bisphosphonate-associated osteonecrosis of the jaw: an immunohistological study. 2011 , 9, 135		21
112	Bisphosphonate related osteonecrosis of the jaw: A minipig large animal model. 2012 , 51, 592-9		66
111	Incidence and risk factors of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients having undergone autologous stem cell transplantation. 2012 , 35, 658-64		29
110	The effect of etidronate on the periodontium of ovariectomized rats. 2012 , 83, 1063-8		9
109	Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment. 2012 , 40, 303-9		151
108	Etiopathogenesis and Clinical Aspects of BIONJ. 2012 , 73-84		
107	BRONJ: The Future. 2012 , 167-178		
106	New approach to analyze genetic and clinical data in bisphosphonate-induced osteonecrosis of the jaw. 2012 , 18, 580-5		16
105	Bisphosphonatassoziierte Kiefernekrose: Pathogenese und Prävention. <i>Der MKG-Chirurg</i> , 2013 , 6, 97-100	0.2	
104	Zoledronic acid inhibits human osteoblast activities. 2013 , 59, 534-41		36
103	Effect of low level laser therapy and zoledronate on the viability and ALP activity of Saos-2 cells. 2013 , 42, 140-6		20
102	Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures. 2013 , 24, 697-705		27
101	Osteonecrosis. 2013 , 249-282		
100	Emerging concepts in the management and treatment of osteonecrosis of the jaw. 2013 , 25, 11-20, v		26

99	Pathologic fractures in bisphosphonate-related osteonecrosis of the jaw-review of the literature and review of our own cases. 2013 , 6, 147-54	21
98	Pathobiology of Cancer Regimen-Related Toxicities. 2013 ,	5
97	Biostimulatory effects of low-level laser therapy on epithelial cells and gingival fibroblasts treated with zoledronic acid. 2013 , 23, 055601	4
96	Association between CYP2C8 (rs1934951) polymorphism and bisphosphonate-related osteonecrosis of the jaws in patients on bisphosphonate therapy: a meta-analysis. 2013 , 129, 90-5	17
95	Osteonecrosis of the external auditory canal associated with oral bisphosphonate therapy: case report and literature review. 2013 , 34, 209-13	17
94	Cytotoxic effects of zoledronic acid on human epithelial cells and gingival fibroblasts. 2013 , 24, 551-8	19
93	Osteonecrosis of the jaw: BRONJ and ARONJ. 2014 , 5, 90-93	8
92	Osteonecrosis of the jaw as a serious adverse effect of bisphosphonate therapy and its indistinct etiopathogenesis. 2014 , 71, 772-6	2
91	Outcomes of osseous free flap reconstruction in stage III bisphosphonate-related osteonecrosis of the jaw: systematic review and a new case series. 2014 , 42, 377-86	23
90	Bisphosphonates: Pharmacology and Clinical Approach to Their Use in Equine Osteoarticular Diseases. 2014 , 34, 727-737	16
89	Low-level laser therapy for osteonecrotic lesions: effects on osteoblasts treated with zoledronic acid. 2014 , 22, 2741-8	12
88	Is bone turnover of jawbone and its possible over suppression by bisphosphonates of etiologic importance in pathogenesis of bisphosphonate-related osteonecrosis?. <i>Journal of Oral and Maxillofacial Surgery</i> , 2014 , 72, 903-10	1.8 30
87	Does an alkaline environment prevent the development of bisphosphonate-related osteonecrosis of the jaw? An experimental study in rats. 2014 , 117, 329-34	24
86	Osteonecrosis of the jaw in patients treated with oral and intravenous bisphosphonates: experience in Sweden. 2014 , 118, 202-8	18
85	The effects of zoledronate on the survival and function of human osteoblast-like cells. 2015 , 16, 355	15
84	Existing data sources for clinical epidemiology: Scandinavian Cohort for osteonecrosis of the jaw - work in progress and challenges. 2015 , 7, 107-16	12
83	Complications of new medications. 2015 , 16, 154-6	1
82	High doses of bisphosphonates reduce osteoblast-like cell proliferation by arresting the cell cycle and inducing apoptosis. 2015 , 43, 396-401	33

81	Bisphosphonate-related osteonecrosis of the jaw: awareness and level of knowledge of Lebanese physicians. 2015 , 23, 2825-31		14
80	The influence of geranylgeraniol on human oral keratinocytes after bisphosphonate treatment: An in vitro study. 2015 , 43, 688-95		12
79	Isoprenoid geranylgeraniol: the influence on cell characteristics of endothelial progenitor cells after bisphosphonate therapy in vitro. <i>Clinical Oral Investigations</i> , 2015 , 19, 1625-33	4.2	13
78	Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development?. 2015 , 43, 847-54		86
77	Impact of Actinomyces naeslundii on bisphosphonate-related osteonecrosis of the jaws in ovariectomized rats with periodontitis. 2015 , 43, 1662-9		7
76	Ibandronate treatment of diffuse sclerosing osteomyelitis of the mandible: Pain relief and insight into pathogenesis. 2015 , 43, 1837-42		25
75	Upregulation of the mevalonate pathway by cholesterol depletion abolishes tolerance to N-bisphosphonate induced VβVβ T cell cytotoxicity in PC-3 prostate cancer cells. 2015 , 357, 279-285		5
74	Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. 2015 , 30, 3-23		680
73	Medication-Related Osteonecrosis of the Jaws. 2015 ,		3
72	In vitro effects of bisphosphonates on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes. <i>Clinical Oral Investigations</i> , 2015 , 19, 139-48	4.2	23
71	The effect of bisphosphonates on the endothelial differentiation of mesenchymal stem cells. 2016 , 6, 20580		20
70	Von der Zellkultur über das Großtiermodell zur Optimierung der klinischen Prophylaxe und Therapie medikamenten-assoziiierter Kiefernekrosen. <i>Der MKG-Chirurg</i> , 2016 , 9, 191-195	0.2	
69	Clinical features of peri-implant medication-related osteonecrosis of the jaw: Is there an association to peri-implantitis?. 2016 , 44, 1945-1951		23
68	Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - A prospective study over 6 years. 2016 , 44, 1689-1693		29
67	Zoledronate Attenuates Accumulation of DNA Damage in Mesenchymal Stem Cells and Protects Their Function. 2016 , 34, 756-67		34
66	Bisphosphonate and Medication-Related Osteonecrosis of the Jaw: A Review. 2016 , 20, 305-314		31
65	Bactericidal efficacy of cold plasma in processed bone. A new approach for adjuvant therapy of medication-related osteonecrosis of the jaw?. 2016 , 4, 9-13		10
64	The role of mylohyoid flap in the treatment of bisphosphonate-related osteonecrosis of the jaws. 2016 , 44, 369-73		21

63	Introducing a protocol to create bisphosphonate-related osteonecrosis of the jaw in rat animal model. 2016 , 44, 271-8		20
62	Uptake of free, calcium-bound and liposomal encapsulated nitrogen containing bisphosphonates by breast cancer cells. 2016 , 86, 58-66		10
61	The Duration and Safety of Osteoporosis Treatment. 2016 ,		
60	Zoledronate induces bisphosphonate-related osteonecrosis of the jaw in osteopenic sheep. <i>Clinical Oral Investigations</i> , 2016 , 20, 31-8	4.2	10
59	Biomarkers for Bisphosphonate-Related Osteonecrosis of the Jaw. 2016 , 18, 281-91		22
58	Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab. <i>Clinical Oral Investigations</i> , 2017 , 21, 127-134	4.2	23
57	Role of microbiological culture and polymerase chain reaction (PCR) of actinomyces in medication-related osteonecrosis of the jaw (MRONJ). 2017 , 45, 357-363		21
56	A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?. 2017 , 28, 2465-2473		63
55	What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review. 2017 , 45, 1493-1502		54
54	Further development of the MRONJ minipig large animal model. 2017 , 45, 1503-1514		27
53	Osteomyelitis der Kieferknochen. 2017 , 26, 236-243		
52	Osteonecrosis. 2017 , 1764-1787.e5		3
51	Medikamentenassoziierte Kiefernekrosen Von der Diagnose zur Therapie. 2017 , 33, 214-223		
50	Effects of an oral bisphosphonate and three intravenous bisphosphonates on several cell types in vitro. <i>Clinical Oral Investigations</i> , 2018 , 22, 2527-2534	4.2	22
49	Double-layer closure techniques after bone surgery of medication-related osteonecrosis of the jaw - A single center cohort study. 2018 , 46, 815-824		34
48	Influence of bisphosphonates on the adherence and metabolism of epithelial cells and gingival fibroblasts to titanium surfaces. <i>Clinical Oral Investigations</i> , 2018 , 22, 893-900	4.2	10
47	In vivo effects of geranylgeraniol on the development of bisphosphonate-related osteonecrosis of the jaws. 2018 , 46, 230-236		14
46	Osteonecrosis of the jaw in patients treated with denosumab: A multicenter case series. 2018 , 46, 1515-1525		36

45	Bisphosphonate Modulation of the Gene Expression of Different Markers Involved in Osteoblast Physiology: Possible Implications in Bisphosphonate-Related Osteonecrosis of the Jaw. 2018 , 15, 359-367	28
44	Molecular and cellular mechanisms for zoledronic acid-loaded magnesium-strontium alloys to inhibit giant cell tumors of bone. 2018 , 77, 365-379	23
43	Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases. 2018 , 69, 177-187	112
42	Influence of pH on osteoclasts treated with zoledronate and alendronate. <i>Clinical Oral Investigations</i> , 2019 , 23, 813-820	4.2 5
41	Synthetic Calcium Phosphate Ceramics as a Potential Treatment for Bisphosphonate-Related Osteonecrosis of the Jaw. 2019 , 12,	7
40	Effects of pH alteration on the pathogenesis of medication-related osteonecrosis of the jaw. 2019 , 122, 45-51	5
39	Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (6), assessment of mandibular metabolism due to long-term administration of an anti-resorptive agent by bone scintigraphy (secondary publication). 2019 , 55, 51-57	2
38	Geranylgeraniol (GGOH) as a Mevalonate Pathway Activator in the Rescue of Bone Cells Treated with Zoledronic Acid: An In Vitro Study. 2019 , 2019, 4351327	13
37	Influence of induced infection in medication-related osteonecrosis of the jaw development after tooth extraction: A study in rats. 2019 , 47, 349-356	11
36	Effect of ProRoot MTA and Biodentine on osteoclastic differentiation and activity of mouse bone marrow macrophages. 2019 , 27, e20180150	5
35	Comorbid conditions are a risk for osteonecrosis of the jaw unrelated to antiresorptive therapy. 2019 , 127, 140-150	3
34	Update on Equine Odontoclastic Tooth Resorption and Hypercementosis. 2020 , 36, 671-689	3
33	A Drug Holiday Reduces the Frequency and Severity of Medication-Related Osteonecrosis of the Jaw in a Minipig Model. 2020 , 35, 2179-2192	12
32	Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals. 2020 , 28, 4019-4029	10
31	Nitrogen-containing bisphosphonate-loaded micro-arc oxidation coating for biodegradable magnesium alloy pellets inhibits osteosarcoma through targeting of the mevalonate pathway. 2021 , 121, 682-694	6
30	The Type of Antiresorptive Treatment Influences the Time to Onset and the Surgical Outcome of Medication-Related Osteonecrosis of the Jaw. <i>Journal of Oral and Maxillofacial Surgery</i> , 2021 , 79, 611-621 ¹⁸	3
29	Wound closure and alveoplasty after preventive tooth extractions in patients with antiresorptive intake-A randomized pilot trial. 2021 , 27, 532-546	8
28	Gingival cell growth with antiresorptive treatment combined with corticosteroids or antiestrogen. 2021 , 7, 465-473	1

27	Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ). 2021 , 57,		12
26	Medication-related osteonecrosis of the jaw (MRONJ) and eNOS Polymorphisms in multiple myeloma patients: a single center experience. 2021 , 21, 272		0
25	Response to the "Letter to the Editor". 2021 ,		
24	Medication-Related Osteonecrosis of the Jaw: A Critical Narrative Review. 2021 , 10,		3
23	Differences between auto-fluorescence and tetracycline-fluorescence in medication-related osteonecrosis of the jaw-a preclinical proof of concept study in the mini-pig. <i>Clinical Oral Investigations</i> , 2020 , 24, 4625-4637	4.2	9
22	Osteonecrosis. 2013 , 1692-1711.e5		1
21	Influence of Bisphosphonates on the Behavior of Osteoblasts Seeded Onto Titanium Discs. 2020 , 31, 304-309		4
20	Postmenopozal dĖemin kadĖalarda dental saĖ ve oral hijyen alĖanĖlarĖa etkisi. 287-293		1
19	Bisphosphonate-associated osteonecrosis of the jaw: are we dealing with a localized non-traditional calciphylaxis?. 2012 , 6, 5-7		7
18	Prevention of medication related osteonecrosis of the jaw after dentoalveolar surgery: An institutionĖ experience. 2020 , 12, e771-e776		3
17	Dental care for patients taking antiresorptive drugs: a literature review. 2019 , 44, e42		4
16	Surgical therapy for medication-related osteonecrosis of the jaw in osteoporotic patients treated with antiresorptive agents. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2020 , 164, 100-107	1.7	7
15	Bisphosphonate-related osteonecrosis of the jaws: A literature review. <i>Oral Biology Research</i> , 2014 , 38, 1-8	0	
14	Local and Microvascular Free Flaps in Patients with Medication-Related Osteonecrosis of the Jaw. 2015 , 93-101		1
13	Pathogenesis of Medication-Related Osteonecrosis of the Jaw. 2015 , 139-148		
12	Osteonecrosis of the Jaw in Association with Targeted Therapy. 2015 , 193-200		
11	Management of Osteonecrosis of the Jaw in Patients Receiving Antiresorptive Treatment. 2016 , 193-202		
10	Epidemiology of Osteonecrosis of the Jaws from Antiresorptive Treatment. 2016 , 185-192		

9	Clodronate ?. 2017 ,		
8	BISPHOSPHONATE INDUCED OSTEONECROSIS OF THE JAWS AND CURRENT THERAPIES. <i>Cumhuriyet Dental Journal</i> , 122-131	0.2	
7	Combined treatment of diffuse sclerosing osteomyelitis of mandible in children. <i>Pediatric Hematology/Oncology and Immunopathology</i> , 2019 , 18, 46-53	0.3	
6	Stress response in periodontal ligament stem cells may contribute to bisphosphonate-associated osteonecrosis of the jaw: A gene expression array analysis. <i>Molecular Medicine Reports</i> , 2020 , 22, 2043-2051	2.9	0
5	Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab. <i>Clinical Oral Investigations</i> , 2021 , 1	4.2	1
4	Antiresorptiva-assoziierte Kiefernekrosen – Ein Update. <i>Der MKG-Chirurg</i> , 2022 , 15, 59-74	0.2	
3	Targeting a therapeutically relevant concentration of alendronate for in vitro studies on osteoblasts. <i>Acta Odontologica Scandinavica</i> , 1-7	2.2	0
2	Effectiveness of local application of simvastatin for prevention of bisphosphonate-related osteonecrosis of the jaw: An animal study on rats. <i>Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology</i> , 2022 ,	0.4	
1	Antiresorptiva-assoziierte Kiefernekrosen. 2023 , 67, 70-74		0